Sugi Predict

Sugi Predict / Compounds / SCHEMBL18689612

SCHEMBL18689612

SCHEMBL18689612

CC(C)(C)OC(=O)N1CCO[C@H](CCN)C1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 1/20 0.49
▸ SMN1; SMN2 Q16637 1/20 0.49
▸ RECQL P46063 1/20 0.44
▸ NR1H2 P55055 1/20 0.40
▸ MAPT P10636 2/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ EPHA2 P29317 4/20 0.39
▸ PDK1 Q15118 3/20 0.39
▸ KDM4E B2RXH2 1/20 0.38
▸ THRB P10828 1/20 0.38
▸ ERBB2 P04626 1/20 0.38
▸ EPHB4 P54760 1/20 0.38
▸ HPGD P15428 1/20 0.37
▸ GPR119 Q8TDV5 1/20 0.36
▸ DPP4 P27487 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19448345 1.00 USP2 (0.49) USP2SMN1; SMN2RECQLNR1H2MAPT
SCHEMBL19439155 1.00 USP2 (0.49) USP2SMN1; SMN2RECQLNR1H2MAPT
Hydrochloric Acid SCHEMBL26629961 0.99 USP2 (0.48) USP2SMN1; SMN2RECQLNR1H2MAPT
SCHEMBL26629957 0.99 USP2 (0.48) USP2SMN1; SMN2RECQLNR1H2MAPT
SCHEMBL20913885 0.92 USP2 (0.47) USP2SMN1; SMN2RECQLNR1H2MAPT
SCHEMBL18669262 0.92 USP2 (0.47) USP2SMN1; SMN2RECQLNR1H2MAPT
SCHEMBL18689545 0.92 USP2 (0.47) USP2SMN1; SMN2RECQLNR1H2MAPT
SCHEMBL23807798 0.90 USP2 (0.44) USP2SMN1; SMN2RECQLNR1H2MAPT
SCHEMBL554849 0.89 USP2 (0.51) USP2SMN1; SMN2RECQLNR1H2MAPT
SCHEMBL60605 0.89 USP2 (0.51) USP2SMN1; SMN2RECQLNR1H2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250325673-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2025-10-23 — — US disclosed
EP-4613773-A2 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2025-09-10 — — EP disclosed
EP-3731869-B1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2025-07-23 — — EP disclosed
US-20230398223-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-12-14 — — US disclosed
US-11723980-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-08-15 — — US disclosed
US-11318205-B1 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2022-05-03 — — US disclosed
US-11318205-B1 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2022-05-03 — — US disclosed
CN-108884083-B Benzo [ B ] furans as bromodomain inhibitors 葛兰素史克知识产权第二有限公司 2022-02-25 — — CN disclosed
CN-108137541-B Pyridone dicarboxamides for use as bromodomain inhibitors 葛兰素史克知识产权第二有限公司 2021-07-06 — — CN disclosed
CN-108884070-B Pyridyl derivatives as bromodomain inhibitors 葛兰素史克知识产权第二有限公司 2021-07-02 — — CN disclosed
US-10370356-B2 Pyridinone dicarboxamide for use as bromodomain inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2019-08-06 — — US disclosed
US-20190192668-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2019-06-27 — — US disclosed
US-20190151279-A1 BENZO[B]FURANS AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2019-05-23 — — US disclosed
US-20190151279-A1 BENZO[B]FURANS AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2019-05-23 — — US disclosed
US-20190119248-A1 PYRIDYL DERIVATIVES AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2019-04-25 — — US disclosed
US-20190119248-A1 PYRIDYL DERIVATIVES AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2019-04-25 — — US disclosed
US-20180282301-A1 PYRIDINONE DICARBOXAMIDE FOR USE AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2018-10-04 — — US disclosed
WO-2017174621-A1 PYRIDYL DERIVATIVES AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2017-10-12 — — WO disclosed
WO-2017174620-A1 BENZO[B]FURANS AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2017-10-12 — — WO disclosed
WO-2017050714-A1 PYRIDINONE DICARBOXAMIDE FOR USE AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2017-03-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10370356-B2 Pyridinone dicarboxamide for use as bromodomain inhibitors BRD4, BRD3, BRDT USP2 2296/4885SMN1; SMN2 3293/4885RECQL 883/4885
US-20250325673-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 USP2 141/4885SMN1; SMN2 2647/4885RECQL 2866/4885
US-11723980-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 USP2 141/4885SMN1; SMN2 2647/4885RECQL 2866/4885
US-20190119248-A1 PYRIDYL DERIVATIVES AS BROMODOMAIN INHIBITORS BRD4, BRD3, BRDT USP2 2873/4885SMN1; SMN2 3654/4885RECQL 852/4885
US-20190151279-A1 BENZO[B]FURANS AS BROMODOMAIN INHIBITORS BRD4, BRD3, BRD2 USP2 1891/4885SMN1; SMN2 3232/4885RECQL 1030/4885
US-20230398223-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 USP2 141/4885SMN1; SMN2 2647/4885RECQL 2866/4885
US-20190192668-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 USP2 141/4885SMN1; SMN2 2647/4885RECQL 2866/4885
US-20180282301-A1 PYRIDINONE DICARBOXAMIDE FOR USE AS BROMODOMAIN INHIBITORS BRD4, BRD3, BRDT USP2 2296/4885SMN1; SMN2 3293/4885RECQL 883/4885
US-11318205-B1 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 USP2 141/4885SMN1; SMN2 2647/4885RECQL 2866/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.